Compare Quest Diagnostics Inc (DGX) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares MSCI India ETF — how do they compare? Quest Diagnostics Inc trades at $204.98 (market cap $22.80B), while iShares MSCI India ETF trades at $48.75. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while iShares MSCI India ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| DGX | INDA | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.02 | $55.29 |
52-Week Low | $166.42 | $45.42 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
INDA trades at $48.79, down 1.03% with a bearish technical signal from moving averages. The India ETF faces mixed sentiment as India's economy grows at 7.8% (CNBC, 2026-06-05) but confronts headwinds from IT sector weakness and Middle East risks. Technical indicators show neutral oscillators with key support at $48.
Outlook remains cautious amid valuation concerns and macroeconomic pressures. Investment opportunity lies in India's long-term growth story, but risks include foreign outflows, geopolitical tensions, and sector-specific challenges in technology and energy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
